Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (3)
  • Open Access

    RETRACTION

    Retraction: Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial

    Xingbang Li1,#, Xuan Zheng2,#, Bowen Jin1, Yunyan Li1, Yongyu Shao1, Xiaoxian Deng1, Dingyang Li1, Shanshan Li1, Hongmei Zhou1, Jie Zhang3, Xianya Zhang4, Qunshan Shen1, Gangcheng Zhang2,*

    Congenital Heart Disease, Vol.18, No.4, pp. 489-489, 2023, DOI:10.32604/chd.2023.031413 - 15 September 2023

    Abstract This article has no abstract. More >

  • Open Access

    ARTICLE

    Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial

    Xingbang Li1,#, Xuan Zheng2,#, Bowen Jin1, Yunyan Li1, Yongyu Shao1, Xiaoxian Deng1, Dingyang Li1, Shanshan Li1, Hongmei Zhou1, Jie Zhang3, Xianya Zhang4, Qunshan Shen1, Gangcheng Zhang2,*

    Congenital Heart Disease, Vol.18, No.3, pp. 373-385, 2023, DOI:10.32604/chd.2023.028979 - 09 June 2023

    Abstract Background: Transcatheter closure of patent foramen ovale (PFO) has been widely accepted as a highly effective way to treat high-risk PFO-related diseases. However, traditional non-degradable occluders made of metal alloys will permanently exist in the body, resulting in thrombosis, valve damage, hemolysis, arrhythmia, or other complications. The biodegradable PFO occluder developed by Shanghai Mallow Medical Instrument Co., Ltd., China can be fully absorbed and degrade into nontoxic ingredients, reducing postoperative complications. Objectives: To study the safety and efficacy of biodegradable PFO occluders in treating PFO. Methods: This single-center clinical trial collected 30 patients treated with a More > Graphic Abstract

    Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial

  • Open Access

    ARTICLE

    Percutaneous Closure of Patent Foramen Ovale and Secundum Atrial Septal Defects with the GORE® CARDIOFORM Septal Occluder: Incidence and Implications of Device Wire Frame Fracture

    Biagio Castaldi1,*, Giulio Cabrelle1, Massimo Padalino2, Vladimiro Vida2, Ornella Milanesi1, Giovanni Di Salvo1

    Congenital Heart Disease, Vol.15, No.5, pp. 347-360, 2020, DOI:10.32604/CHD.2020.012750 - 23 September 2020

    Abstract Background: Trans-catheter closure has become the treatment of choice for patent foramen ovale (PFO) and ostium secundum atrial septal defects (ASD). A wide variety of devices are commercially available, however, concerns have been raised about the risk of cardiac erosion associated with stiff/rigid devices. The GORE® CARDIOFORM Septal Occluder (GSO) is a double-disc, soft and conformable device with no reported incidence of cardiac erosions. However, wire frame fracture (WFF) have been reported. Aim: To assess the incidence and clinical significance of WFF after GSO implantation in paediatric patients. Methods: Seventy-seven consecutive patients were enrolled. Periprocedural and follow-up… More >

Displaying 1-10 on page 1 of 3. Per Page